Paper Review Records
全部论文审稿周期
27 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
81
天
Impact of race/ethnicity, donor and recipient age, and donor on survival after allogeneic transplant in the post-transplant cyclophosphamide era
作者
Megan M. Herr; Nisha M. Nair; Nandita Khera; Shernan G. Holtan; Theresa Hahn展开收起
作者单位
1. Roswell Park Comprehensive Cancer Center, Buffalo, USA; 2. Mayo Clinic, Phoenix, USA展开收起
194
天
Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402)
作者
Douglas W. Sborov; Anuj K. Mahindra; Vera J. Suman; Elisabet Esteve Manasanch; Prashant Kapoor; Tibor Kovacsovics; Cesar Rodriguez; Benjamin Parsons; Jose Eugenio Najera; Lyle Goldman; Destin Carlisle; Yujia Wen; Shira H. Dinner; Ilene A. Galinsky; LeAnne Kennedy; James Omel; Philip McCarthy; Saad Usmani; Paul G. Richardson展开收起
作者单位
1. University of Utah, Huntsman Cancer Institute, Salt Lake City, USA; 2. Scripps MD Anderson Cancer Center, La Jolla, USA; 3. Alliance Statistics Data and Management Center, Mayo Clinic, Rochester, USA; 4. University of Texas MD Anderson Cancer Center, Houston, USA; 5. Mayo Clinic, Rochester, USA; 6. City of Hope Cancer Center, Phoenix, USA; 7. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; 8. Gundersen Health, La Crosse, USA; 9. Cancer Centers of Southwest Oklahoma, Oklahoma, USA; 10. Ascension Health, Southfield, USA; 11. Alliance Protocol Operations Office, University of Chicago, Chicago, USA; 12. Dana-Farber/Partners Cancer Care, Boston, USA; 13. Wake Forest Baptist Health/Atrium Health Wake Forest Baptist, Winston-Salem, USA; 14. Roswell Park Comprehensive Cancer Center, Buffalo, USA; 15. Memorial Sloan Kettering Cancer Center, New York, USA; 16. Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, USA展开收起
85
天
Impact of residual clonal plasma cell proliferation rate after autologous stem cell transplant on outcomes in multiple myeloma
作者
Tamer Hellou; Daniel G. Packard; Maximilian J. Steinhardt; Shaji K. Kumar; Angela Dispenzieri; Saurabh Zanwar; Shinichiro Suzuki; Estefania Gauto Mariotti; Dragan Jevremovic; Horatiu Olteanu; Pedro Horna; Gregory Otteson; Francis K. Buadi; David Dingli; Suzanne R. Hayman; Prashant Kapoor; Nelson Leung; Joselle Cook; Nadine Abdallah; Moritz Binder; Rahma Warsame; Taxiarchis V. Kourelis; Ronald S. Go; Yi Lin; Eli Muchtar; S. Vincent Rajkumar; Wilson I. Gonsalves; Morie A. Gertz展开收起
作者单位
1. Division of Hematology, Mayo Clinic, Rochester, USA; 2. Internal Medicine, Mayo Clinic, Rochester, USA; 3. Department of Medical Oncology, Mayo Clinic, Rochester, USA; 4. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA展开收起
140
天
Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)
作者
Melinda SY Tan; Kye Ling Wong; Cinnie Soekojo; Chandramouli Nagarajan; Sarah Burkhill; Xinhua Li; Ho-Jin Shin; Jong Heon Jung; Yeung-Chul Mun; Ho-Young Yhim; Jae Hoon Lee; Ling Cao; Tadao Ishida; Chihiro Shimazaki; Makoto Sasaki; Hiroyuki Takamatsu; Shinsuke Iida; Hirono Iriuchishima; Shuji Ozaki; Karen Tang; Jeffrey Huang; Jerry Teng; Cheng-Shyong Chang; Changki Min; Wenming Chen; Hiroshi Handa; Kihyun Kim; Priti Bahety; Juan Du; Wee Joo Chng展开收起
作者单位
1. Department of Hematology, Singapore General Hospital, Singapore, Singapore; 2. Department of Hematology, National Cancer Center Singapore, Singapore, Singapore; 3. National University Cancer Institute of Singapore, Singapore, Singapore; 4. Singapore Clinical Research Institute, Singapore, Singapore; 5. Pusan National University Hospital, Busan, South Korea; 6. National Cancer Center, Goyang, South Korea; 7. Ewha Womens University Mokdong Hospital, Seoul, South Korea; 8. Jeonbuk National University Hospital, Jeonju, South Korea; 9. Gachon University Gil Medical Center, Incheon, South Korea; 10. Tan Tock Seng Hospital, Singapore, Singapore; 11. Japan Red Cross Medical Center, Tokyo, Japan; 12. JCHO Kyoto Kuramaguchi Medical Center, Kyoto, Japan; 13. Juntendo University Hospital, Bunkyo, Japan; 14. Kanazawa University Hospital, Kanazawa, Japan; 15. Nagoya City University Hospital, Nagoya, Japan; 16. Shibukawa Medical Center, Shibukawa, Japan; 17. Tokushima Prefectural Central Hospital, Tokushima, Japan; 18. Queen Mary Hospital, Hong Kong University, Hong Kong, Hong Kong; 19. National University Taiwan Hospital, Taipei, Taiwan; 20. Taichung Veterens General Hospital, Taichung, Taiwan; 21. Chang Bing Show Chwan Memorial Hospital, Lukang, Taiwan; 22. Seoul Saint Mary’s Hospital, Seoul, South Korea; 23. Beijing Chaoyang Hospital, Beijing, China; 24. Gunma University School of Medicine, Maebashi, Japan; 25. Samsung Medical Center Samsung Medical Center, Seoul, South Korea; 26. GlaxoSmithKline Pte Ltd, Singapore, Singapore; 27. Shanghai Chang Zheng Hospital, Shanghai, China展开收起
91
天
Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study
作者
Elizabeth K. O’Donnell; Omar Nadeem; Jacob P. Laubach; Giada Bianchi; Andrew R. Branagan; Brea C. Lipe; Paul G. Richardson; Ehsan Malek; Robb S. Friedman; Ajay K. Nooka; Robert Redd; Noopur S. Raje; Andrew J. Yee展开收起
作者单位
1. Mass General Brigham Cancer Institute, Boston, USA; 2. Harvard Medical School, Boston, USA; 3. Dana-Farber Cancer Institute, Boston, USA; 4. University of Rochester Medical Center, Rochester, USA; 5. University Hospitals of Cleveland, Cleveland, USA; 6. Roswell Park Comprehensive Cancer Center, Buffalo, USA; 7. Newton-Wellesley Hospital, Newton, USA; 8. Dana-Farber Brigham Cancer Center at South Shore Health, South Weymouth, USA; 9. Winship Cancer Institute, Emory University, Atlanta, USA展开收起
74
天
Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial
作者
Steffen Koschmieder; Susanne Isfort; Lino L. Teichmann; Philippe Schafhausen; Florian H. Heidel; Carl Crodel; Andreas Hochhaus; Martin Griesshammer; Katja Sockel; Philipp J. Jost; Denise Walther; Konstanze Döhner; Joachim R. Göthert; Markus Radsak; Marinela Augustin; Heiko Becker; Aristoteles Giagounidis; Markus Schaich; Martine Klausmann; Nikolas von Bubnoff; Frank Stegelmann; Maike Kortmann; Michelle Zentis; Julia Frank; Anna Hagemeier; Martin Hellmich; Tim H. Brümmendorf展开收起
作者单位
1. Department of Medicine (Hematology, Oncology, Hemostaseology, and SCT), Faculty of Medicine, RWTH Aachen University, Aachen, Germany; 2. Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany; 3. Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany; 4. Department of Medicine III, University Hospital Bonn, Bonn, Germany; 5. Department of Oncology, Hematology, and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6. Clinic for Internal Medicine 2, Jena University Hospital, Jena, Germany; 7. University Clinic for Haematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Centre Minden, University of Bochum, Minden, Germany; 8. Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Germany; 9. Medical Department III, Hematology and Oncology, and Center for Translational Cancer Research, Translatum, Technical University of Munich, Munich, Germany; 10. Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Graz, Austria; 11. Department of Hematology/Oncology and Cell Therapy, Otto-von-Guericke University Magdeburg, Medical Center, Magdeburg, Germany; 12. Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; 13. Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany; 14. Department of Hematology and Medical Oncology, UCT Mainz, DKTK, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany; 15. Klinikum Nürnberg Nord, Klinik für Innere Medizin 5, Schwerpunkt Onkologie/Hämatologie, Paracelsus Medizinische Privatuniversität, Campus Nürnberg, Nürnberg, Germany; 16. Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center, Faculty of Medicine, German Cancer Consortium (DKTK), partner site Freiburg, University of Freiburg, Freiburg, Germany; 17. Dept. Oncology, Hematology and Palliative Care, Marienhospital Düsseldorf, Düsseldorf, Germany; 18. Department of Hematology, Oncology and Palliative Medicine, Rems-Murr-Klinikum, Winnenden, Germany; 19. Gemeinschaftspraxis, Aschaffenburg, Germany; 20. Department of Hematology and Oncology, University Medical Center Schleswig-Holstein and University Cancer Center Schleswig-Holstein (UCCSH), University of Lübeck, Lübeck, Germany; 21. Center for Translational & Clinical Research (CTC-A), Faculty of Medicine, RWTH Aachen University, Aachen, Germany; 22. Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; 23. Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany展开收起
FAQ
Blood Cancer Journal审稿要多久?
截至2026-11-18,CrushSCI 收录了 Blood Cancer Journal 的 27 篇完整审稿记录。最快一篇从收稿到录用用了 19 天(Treatment of adult acute lymphoblastic leukemia—a therapeutic revolution in the making,2026-06-24 收稿,2026-07-13 录用),最慢一篇用了 203 天;平均 104.4 天,中位数 91 天。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
